• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Poll: What Is Your Prediction for 2021?

Article

The year 2021 could bring momentous developments in the biosimilar field.

Which do you think is most likely to occur in 2021?

The Supreme Court strikes down the whole Affordable Care Act and its biosimilar approval pathway.
The FDA approves the first insulin biosimilar.
Innovator companies launch lower-cost "authorized biologics" in response to biosimilar competition.
The FDA approves the first interchangeable biosimilar.

See what our Advisory Board had to say about 2020 and 2021 in biosimilars.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Subscribe Now!
Recent Videos
Here are the top 5 biosimilar articles for the week of August 25, 2025.
Here are the top 5 biosimilar articles for the week of August 11, 2025.
The Top 5 Biosimilar Articles for the Week of August 4
Related Content
health worker and medication revenue data | Image credit: vadish - stock.adobe.com

Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

Skylar Jeremias
August 31st 2025
Article
CFB podcast banner

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

Skylar Jeremias;Giuseppe Randazzo;Hillel P. Cohen, PhD
August 31st 2025
Podcast
Thrombopoietin receptor agonists such as romiplostim have become a cornerstone of ITP treatment by stimulating platelet production, and biosimilars offer a more affordable option. | Image Credit: Anusorn - stock.adobe.com

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

Rose McNulty
August 31st 2025
Article
CFB podcast banner

Escaping the Void: All Things Biosimilars With Craig & G

Craig Burton;Giuseppe Randazzo;Skylar Jeremias
August 31st 2025
Podcast
stem cells and donor mobilization | Image credit: sola_sola - stock.adobe.com

Ten Years of Data Support Safety of Biosimilar Filgrastim for Donor Mobilization

Skylar Jeremias
August 31st 2025
Article
america health and biosimilars | Image credit: MohamadFaizal - stock.adobe.com

Litigation, Launch, and Lower Costs: 3 Big Moves in the US Biosimilar Space

Skylar Jeremias
August 31st 2025
Article
© 2025 MJH Life Sciences

All rights reserved.